Recurrent Endometrial Cancer
Information
- Disease name
- Recurrent Endometrial Cancer
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05263492 | Active, not recruiting | Phase 2 | Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer | April 1, 2022 | September 30, 2025 |
| NCT02899793 | Active, not recruiting | Phase 2 | Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer | September 2016 | October 2025 |
| NCT02549989 | Completed | Phase 2 | Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer | September 2015 | March 23, 2022 |
| NCT02755844 | Completed | Phase 1/Phase 2 | Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients | September 23, 2016 | June 2020 |
| NCT02788708 | Completed | Phase 1 | Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | May 27, 2016 | March 31, 2022 |
| NCT06366347 | Not yet recruiting | Phase 2 | ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab | September 2024 | March 1, 2029 |
| NCT03564340 | Recruiting | Phase 1/Phase 2 | Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers | May 21, 2018 | June 21, 2026 |
| NCT05798611 | Recruiting | Phase 2 | Study of ART0380 in Patients With Biologically Selected Solid Tumors | September 6, 2023 | March 2025 |
| NCT04906382 | Terminated | Early Phase 1 | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer | July 1, 2021 | September 1, 2022 |
| NCT03277482 | Terminated | Phase 1 | Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | June 1, 2018 | July 15, 2022 |
| NCT01454479 | Unknown status | Phase 1 | A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma | March 2011 | April 2014 |
| NCT04197219 | Withdrawn | Phase 2 | Pembrolizumab With Axitinib in Recurrent Endometrial Cancer | February 1, 2021 | December 1, 2026 |
| NCT05419817 | Withdrawn | Phase 2 | Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System | September 8, 2022 | December 2026 |
| NCT02117817 | Withdrawn | Phase 1 | Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer | February 2015 | February 25, 2015 |